0001104659-23-059680.txt : 20230512
0001104659-23-059680.hdr.sgml : 20230512
20230512154324
ACCESSION NUMBER: 0001104659-23-059680
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230510
FILED AS OF DATE: 20230512
DATE AS OF CHANGE: 20230512
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sabba Stephen L
CENTRAL INDEX KEY: 0001442372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 23915281
MAIL ADDRESS:
STREET 1: DORSET MANAGEMENT CORP
STREET 2: 485 UNDERHILL BLVD SUITE 205
CITY: SYOSSET
STATE: NY
ZIP: 11791
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
tm2315666-1_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-05-10
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001442372
Sabba Stephen L
DORSET MANAGEMENT CORP
485 UNDERHILL BLVD SUITE 205
SYOSSET
NY
11791
1
0
0
0
0
Common Stock
2023-05-10
4
M
0
6408
0.00
A
32192
D
Common Stock
2023-05-10
4
S
0
6408
77.1262
D
25784
D
Non-Qualified Stock Option (right to buy)
18.82
2023-05-10
4
M
0
6408
0
D
2023-06-11
Common Stock
6408
927
D
These securities, as represented in Column 5, include a grant of 1,723 restricted shares approved by the Board of Directors of the Company at the 2022 Meeting ("2022 Shares"), which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. As reported on the Reporting Person's Form 4 dated 14 June 2022, which was filed to reflect the 2022 Meeting grant, the original grant was for 1,004 2022 Shares. The reference to 1,732 2022 Shares reflects certain adjustments by the Company to the 2022 Shares following the Company's 1 November 2022 distribution of a legacy business.
The price reported in Column 4 is an average. These shares were sold in separate transactions for the following number of shares and at the respective prices: $77.29 (100), $77.25 (8), $77.23 (41), $77.22 (36), $77.21 (201), $77.20 (372), $77.18 (800), $77.17 (120), $77.16 (34), $77.15 (971), $77.14 (1,305), $77.13 (151), $77.12 (1), $77.11 (239), $77.10 (101), $77.09 (100), $77.08 (1,065), $77.01 (9), and $77.00 (754). This disposition was reported on a Form 144 for filed 10 May 2023.
These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2013 Meeting, as previously reported on the Reporting Persons Form 4 dated 13 June 2013. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time.
By: /s/ Stephen L. Sabba
2023-05-12